Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy

被引:19
|
作者
Lee, LW
McBain, CA
Swindell, R
Wylie, JP
Cowan, RA
Logue, JP [1 ]
机构
[1] Christie Hosp, Dept Clin Oncol, Manchester M20 4BX, Lancs, England
[2] Christie Hosp, Dept Med Stat, Manchester, Lancs, England
关键词
prostate cancer; radical prostatectomy; radiotherapy; salvage;
D O I
10.1016/j.clon.2004.07.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To review the outcome of men receiving hypofractionated salvage radiotherapy for rising prostate-specific antigen (PSA) after radical prostatectomy. Materials and methods: A. retrospective analysis of 61 men referred for salvage radiotherapy for biochemical relapse after radical prostatectorny was conducted. Twenty-four men receiving hormonal therapy or with follow-up of less than 12 months were excluded. Thirty-seven men were identified, median age 64 years, median preoperative PSA 11 ng/ml (5.6-60 ng/ml), Gleason scores < 7: 70%, Gleason scores greater than or equal to 7: 30%. Twenty-seven men had positive surgical resection margins, eight had seminal-vesicle involvement and one had lymph-node involvement. Diagnosis of failure after radical prostatectomy was made on rising PSA in all cases; 19 men also had positive magnetic resonance imaging, 11 abnormal digital rectal examination and nine positive biopsy. Radiotherapy was delivered conformally to the prostatic fossa, 50-52.5 Gy in 20 fractions over 4 weeks. Date of failure after radiotherapy was defined by the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus criteria or as date of commencement of hormonal therapy for rising PSA. Results: Median time front radical prostatectorny to radiotherapy was 30.6 months (8-68 months); median pre-radiotherapy PSA was 2.9 ng/ml (0.5-11.4 ng/ml). PSA response after radiotherapy was seen in 33 out of 37 (89%) patients. At median follow-up of 36 months (20-85 months), 28 out of 37 remained disease-free. Thirteen more patients have had two consecutive PSA rises. Actuarial 3-year disease-free survival is 74%. No patient has developed metastases or died of prostate cancer. Pre-radiotherapy PSA less than 2 ng/ml predicted disease-free survival (P = 0.027). No acute toxicity greater than Radiation Therapy Oncology Group (RTOG) G2 was observed. Conclusions: Salvage radiotherapy after radical prostatectomy achieved durable biochemical control in most patients. Outcome is improved if radiotherapy is delivered when PSA is less than 2 ng/ml. A policy of close monitoring after radical prostatectomy with early referral for salvage radiotherapy is advocated. (C) 2004 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:517 / 522
页数:6
相关论文
共 50 条
  • [1] OUTCOME AFTER CONFORMAL SALVAGE RADIOTHERAPY IN PATIENTS WITH RISING PROSTATE-SPECIFIC ANTIGEN LEVELS AFTER RADICAL PROSTATECTOMY
    Geinitz, Hans
    Riegel, Martina G.
    Thamm, Reinhard
    Astner, Sabrina T.
    Lewerenz, Carolin
    Zimmermann, Frank
    Molls, Michael
    Nieder, Carsten
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (05): : 1930 - 1937
  • [2] Salvage radiotherapy in patients with persisting prostate-specific antigen after radical prostatectomy for prostate cancer
    Bottke, D
    Wiegel, T
    Höcht, S
    Müller, M
    Schostak, M
    Hinkelbein, W
    ONCOLOGY, 2003, 65 : 18 - 23
  • [3] SALVAGE RADIOTHERAPY FOR RISING PROSTATE-SPECIFIC ANTIGEN LEVELS AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER: DOSE-RESPONSE ANALYSIS
    Bernard, Johnny Ray, Jr.
    Buskirk, Steven J.
    Heckman, Michael G.
    Diehl, Nancy N.
    Ko, Stephen J.
    Macdonald, Orlan K.
    Schild, Steven E.
    Pisansky, Thomas M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (03): : 735 - 740
  • [4] Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years
    Anscher, MS
    Clough, R
    Dodge, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (02): : 369 - 375
  • [5] Several Questions About Prostate-Specific Antigen and Salvage Radiotherapy After Radical Prostatectomy
    Mai, Zhipeng
    Yan, Weigang
    Zhou, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (23) : 3956 - +
  • [6] Several Questions About Prostate-Specific Antigen and Salvage Radiotherapy After Radical Prostatectomy Reply
    Tilki, Derya
    Chen, Ming-Hui
    D'Amico, Anthony V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (23)
  • [7] Salvage radiotherapy for rising prostate specific antigen after radical prostatectomy for prostate cancer: Dose response analysis
    Buskirk, S. J.
    Pisansky, T. M.
    Schild, S. E.
    Macdonald, O. K.
    Wong, W. W.
    Kozelsky, T. F.
    Heckman, M. G.
    Crook, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S322 - S322
  • [8] Management of patients with rising prostate-specific antigen after radical prostatectomy
    Laufer, M
    Pound, CR
    Carducci, MA
    Eisenberger, MA
    UROLOGY, 2000, 55 (03) : 309 - 315
  • [9] Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy
    Campbell, Shauna R.
    Tom, Martin C.
    Agrawal, Shree
    Efstathiou, Jason A.
    Michalski, Jeff M.
    Abramowitz, Matthew C.
    Pollack, Alan
    Spratt, Daniel E.
    Hearn, Jason W. D.
    Stephans, Kevin L.
    Gao, Tianming
    Li, Jianbo
    Tendulkar, Rahul D.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (03): : 304 - 313
  • [10] Radiotherapy after radical prostatectomy in patients with prostate-specific antigen elevation
    Wiegel, T
    Hinkelbein, W
    CONTROVERSIES IN URO-ONCOLOGY, 2002, 36 : 35 - 42